Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  St. Jude Medical, Inc.    STJ

Delayed Quote. Delayed  - 07/29 10:04:12 pm
83.04 USD   +0.46%
07/27DJAlere Faces Criminal Probe Over Medicare, Medicaid Billing
07/26 Glenmede Trust Company Na Decreased Stake in Illinois Tool Works ..
07/21 With acquisition pending, St. Jude Medical's rivals 'licking thei..
News SummaryMost relevantAll newsSector news 

St. Jude Medical, Inc. : St Jude To Stop Selling Another Version Of Defibrillator Wires

share with twitter share with LinkedIn share with facebook
share via e-mail
04/04/2012 | 03:48pm CEST

St. Jude Medical Inc. (STJ) will stop selling another version of its defibrillator wires in an effort to head off potential problems like those the medical-device maker is currently battling with its Riata and Riata ST wires.

The Riata defibrillator wires, called leads, are no longer on the market but are still implanted in thousands of patients in the U.S. In a medical journal last month, prominent cardiologist Robert G. Hauser wrote that the cables are responsible for at least 20 deaths.

Wednesday, the company said it will cease selling its QuickSite and QuickFlex left-ventricular leads used to connect cardiac resynchronization therapy devices to the heart. Roughly 171,000 QuickSite and QuickFlex leads have been sold worldwide.

The decision comes as St. Jude has confirmed 39 cases of the metal wires wearing through their silicone covering, leading to an incidence rate of 2.3 in every 10,000 leads. Still, it stressed that its decision to stop selling the wires is a proactive one.

"It is important to note, however, that the overall safety and reliability of QuickSite and QuickFlex leads continues to be comparable to currently available CRT leads from other manufacturers," the company wrote.

The wire leads connect life-saving medical devices, which are placed under the skin in the shoulder area, to the heart and delivers a jolt that restores proper rhythm. Because of the constant pounding motion of the heart, the thin leads can be damaged.

Shares closed Tuesday at $43.80 and were inactive in premarket trading. The stock is up roughly 36% from lows hit late last year when the Food and Drug Administration termed the Riata defibrillator issues as a Class I recall, which applies to grave dangers like chance of death.

   -By Mia Lamar, Dow Jones Newswires; 212-416-3207; mia.lamar@dowjones.com 

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on ST. JUDE MEDICAL, INC.
07/28 ST JUDE MEDICAL : Patent Issued for Commissure Attachment Feature for Prosthetic..
07/28 ST JUDE MEDICAL : Patent Issued for System and Method for Detecting Sheathing an..
07/28 ST JUDE MEDICAL : "Transcatheter Valve with Lyophilized Tissue" in Patent Applic..
07/28 ST JUDE MEDICAL : An Application for the Trademark "MERLIN" Has Been Filed by St..
07/27DJAlere Faces Criminal Probe Over Medicare, Medicaid Billing
07/27 ST JUDE MEDICAL : Assigned Patent
07/26 Glenmede Trust Company Na Decreased Stake in Illinois Tool Works by $29.03 M..
07/21 ST JUDE MEDICAL : An Application for the Trademark "INQUIRY" Has Been Filed by S..
07/21 ST JUDE MEDICAL : Trademark Application for "THERAPY" Filed
07/21 ST JUDE MEDICAL : Patent Application Titled "Ablation Catheter Designs and Metho..
More news
Sector news : Medical Devices & Implants
07/28DJZIMMER BIOMET : Boosts Bottom End of Earnings Forecast as Loss Narrows
07/28 Weak China sales drag down Smith & Nephew profits
07/26DJBAXTER : Results Boosted by Growth in Hospital Products Segment
07/25DJBAXTER : CFOs Turn to Consultants as Challenges Mount
07/22DJDEXCOM : Shares Rise After FDA Panel Vote
More sector news : Medical Devices & Implants
News from SeekingAlpha
07/25 Smith & Nephew Continues To Impress
07/22 Healthcare ratings - upgrades/downgrades
07/20 St. Jude Medical (STJ) Michael T. Rousseau on Q2 2016 Results - Earnings Call..
07/20 St. Jude Medical Q2 revenues up 11%; Non-GAAP EPS up 3%
07/20 St. Jude Medical EPS in-line, beats on revenue
Financials ($)
Sales 2016 6 052 M
EBIT 2016 1 515 M
Net income 2016 938 M
Debt 2016 4 821 M
Yield 2016 1,43%
P/E ratio 2016 25,98
P/E ratio 2017 21,27
EV / Sales 2016 4,70x
EV / Sales 2017 4,32x
Capitalization 23 606 M
More Financials
Duration : Period :
St. Jude Medical, Inc. Technical Analysis Chart | STJ | US7908491035 | 4-Traders
Full-screen chart
Technical analysis trends ST. JUDE MEDICAL,...
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus HOLD
Number of Analysts 22
Average target price 79,0 $
Spread / Average Target -4,9%
Consensus details
EPS Revisions
More Estimates Revisions
Michael T. Rousseau President, Chief Executive Officer & Director
Daniel J. Starks Executive Chairman
Scott P. Thome Vice President-Global Operations & Supply Chain
Donald J. Zurbay Chief Financial Officer & Vice President
Mark D. Carlson Chief Medical Officer & VP-Global Clinical Affairs
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ST. JUDE MEDICAL, INC.34.43%23 606
SMITH & NEPHEW PLC2.90%14 654
ENDOLOGIX, INC.42.53%1 154
GLAUKOS CORP41.60%1 137
More Results